Future Market Insights reports that the fungal staining reagent market is estimated to secure a valuation of US$ 3.4 billion in 2023 and is estimated to rise to US$ 5.0 billion by 2033. The market is anticipated at a CAGR of 4.1% during the forecast period. The factors accelerating the demand for fungal staining reagents are as follows-
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | US$ 3.4 billion |
| Projected Market Value in 2033 | US$ 5.0 billion |
| Growth Rate (2023 to 2033) | CAGR of 4.1% |
The growing concern of systematic fungal infection caused by microorganisms like cryptococcusneoformans and candidiasis boost the market growth in some region. Increased development in the field of skin infections and increased demand for the treatment of candidiasis are creating new opportunities for the growth of the fungal staining reagents market. Growing awareness among consumers regarding co-infection with fungi is the major factor driving the growth of the fungal staining reagent market over the forecast period.
The fungal staining reagents market is expected to be dominated by North America on account of increased research application of fungal staining reagents and increased advances in laboratory settings. Also, the increased incidences of medical-associated infections in the USA and growing advances in healthcare settings are expected to drive market growth in the region.
On the other hand, the fungal staining reagents market in Europe is witnessing significant growth in recent years. Several companies in Europe are providing fungal staining reagents to meet the growing demand due to increased concern about fungal infections like candida auris infection.
Asia Pacific is expected to account for the highest market share of the fungal staining reagent market during the forecast period owing to the increasing investment in research and development activities and growing innovation in reagents.
The leading players operating in the fungal staining reagent market are teco diagnostics, Biocare Corporation, I-SENS Inc, VivaCheck Laboratories Inc, Vmed Technology, SunTech Medical Inc, IDEXX Laboratories Inc, Zoitis Inc, Merck KGaA, Darmstadt, HiMedia Laboratories among other.
The global fungal staining reagents market is highly fragmented owing to the presence of a large number of domestic manufacturers Key players in this market are implementing various strategies, including collaboration, partnerships through mergers and acquisitions, strategic collaborations, and geographical expansions to expand their market presence.
The fungal staining reagents market is expected to grow in coming years owing to the increased demand for accurate and rapid diagnosis of fungal infection and growing advances in staining technology. Also, the increased use of fungal staining reagents in hospitals, diagnostic centers, and others increases the sales of the market. Several start-ups have entered the fungal staining reagents market with innovative products and technology.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by Future Market Insights, Fungal Staining Reagent market is set to experience growth during the year 2021-2031. Fungal stains continue to be an important tool in the diagnostic staging of tissue laboratories for characterizing infectious microorganisms.
Dermatophytes, or superficial fungal infections involving the skin, rarely pose serious health problems for men. However, systemic fungal infections caused by microorganisms such as Cryptococcusneoformans and Candidaalbicans can cause life-threatening infections, especially in immunocompromised people.
It is important to consider the fungal disease in relation to the 2019 pandemic of coronavirus infection (COVID19) because the symptoms of some fungal disease May be similar to those of COVID19, including fever, cough and shortness of breath. Clinical tests are needed to determine whether a person has a fungal infection or COVID19 to provide adequate treatment.
Fungal infections are common in people infected with HIV/AIDS, organ transplant patients, cancer patients, hospitalized patients, stem cell transplant patients and people with weakened immune system. Therefore, when signs of fungal infection are observed on H&E staining, fungal stains are often urgently ordered by a surgical pathologist. Schiff’s reagent and hexamine silver solution stain. Grocott's Silver (GMS) staining is perhaps the most widely used fungal stain.
Some pathologists order acid Schiff (PAS) staining regularly, expecting to achieve faster and more reliable staining. This method is one of the most frequently used methods in tissue laboratories. Relatively simple and reliable to run even with inexperienced hands. Increasing prevalence of fungal infections propel the growth of fungal staining reagent market.
Principal Consultant
People with severe COVID-19 who seem to be in an intensive care unit (ICU) are particularly vulnerable to bacterial or fungal infections. Co-infection with these fungi is increasing in frequency, reported, and can be associated with serious illness and death.
Awareness of the potential for co-infection with fungi is essential to reduce delays in diagnosis and treatment in order to prevent serious illness and death from these infections. Thus, rise in incidence of Fungal Diseases is expected to boost the demand for Fungal Staining Reagent.
Medical-associated infections, such as candidiasis, are a major concern in the United States. With advances and changes in medical practice, there is a possibility that new drug-resistant bacteria may appear in the medical field. According to CDC, Based on fungal disease management coding data, direct medical expenses were $7.2 billion in 2017.
Including overhead and social costs can result in much higher total costs. In 2017, there were more than 75,000 hospitalizations and approximately 9 million outpatient visits for fungal diseases. However, these figures may be significantly underestimated due to lack of diagnostics and lack of coding. In 2017, there were approximately 23,000 cases of invasive Candida.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There are concerns about an increase in Candida auris infection, a fungus that is difficult to control in Europe. Fungi can easily spread in the medical environment and cause invasive infections, and my achievements for several types of antifungal agents are also relevant. Due to the difficulty of identifying the laboratory and the lack of recognition of this new Candida species, radio waves and onset can remain unobtrusive.
Some of the key players operating in the Fungal Staining Reagent market are
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
Fungal Staining Reagent Market
